A deeper understanding of checkpoint inhibitors like PD-1/PD-L1 and CTLA-4 has paved the way for advancements in monoclonal antibodies (mAbs) targeting these proteins, improving cancer therapy. This evidence concerns the gene CTLA4 and cancer.